

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Brii Biosciences Limited**  
**騰盛博藥生物科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2137)**

## **POSTPONEMENT OF EXTRAORDINARY GENERAL MEETING**

Reference is made to (i) the announcement (the “**Announcement**”) of Brii Biosciences Limited (the “**Company**”) dated August 2, 2023 in relation to the closure of register of members of the Company, and (ii) the circular (the “**Circular**”) and the notice (the “**Notice**”) of the extraordinary general meeting (the “**EGM**”) of the Company both dated August 4, 2023 in relation to the termination of the Existing Share Option Scheme and the adoption of the 2023 Share Option Scheme and the termination of the Existing Share Award Scheme and the adoption of the 2023 Share Award Scheme. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

### **POSTPONEMENT OF THE EGM**

As set out in the Circular, the EGM was originally scheduled to be held on Monday, August 21, 2023 at 9:00 a.m. (Hong Kong time). Due to administrative reason, the Company has decided to postpone the EGM to Friday, September 1, 2023 at 9:00 a.m. (Hong Kong time) (the “**Postponed EGM**”). The Postponed EGM will remain to be held online via the Tricor e-Meeting System. The login credentials remain unchanged as sent to Shareholders and proxies.

For the purpose of determining the eligibility of the Shareholders to attend and vote at the EGM, the register of members of the Company was originally scheduled to be closed from Wednesday, August 16, 2023 to Monday, August 21, 2023 (both days inclusive). For the avoidance of doubt, the period for closure of the register of members of the Company will remain unchanged for the Postponed EGM.

### **FORM OF PROXIES FOR THE POSTPONED EGM**

All resolutions as set out in the Notice will remain unchanged for the Postponed EGM. The forms of proxy for use at the EGM, which have been despatched to the Shareholders on August 4, 2023 (the “**Form(s) of Proxy**”) together with the Circular and the Notice, will remain valid and applicable for use at the Postponed EGM.

Shareholders who have not yet returned the Forms of Proxy but intend to appoint a proxy to attend the Postponed EGM are required to complete and return the Forms of Proxy in accordance with the instructions printed thereon to the Company's branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, not less than 48 hours before the time appointed for holding the Postponed EGM (i.e. not later than Wednesday, August 30, 2023 at 9:00 a.m. (Hong Kong time)) or any adjournment thereof (as the case may be). For the avoidance of doubt, any Form of Proxy duly completed and returned in accordance with the instructions printed thereon remains valid for the Postponed EGM and the relevant Shareholders are not required to submit the Form of Proxy again.

Save for the aforesaid changes, all other information and contents as set out in the Circular, the Notice and the Form of Proxy remain unchanged.

By order of the Board  
**Brii Biosciences Limited**  
**Dr. Zhi Hong**  
*Chairman*

Hong Kong, August 20, 2023

*As at the date of this announcement, the Board comprises Dr. Zhi Hong and Dr. Ankang Li as executive directors; Mr. Robert Taylor Nelsen as non-executive director; and Dr. Martin J Murphy Jr, Ms. Grace Hui Tang, Mr. Yiu Wa Alec Tsui, Mr. Gregg Huber Alton and Dr. Taiyin Yang as independent non-executive directors.*